Cargando…

Sorafenib Combined with Transarterial Chemoembolization versus Transarterial Chemoembolization Alone for Advanced-Stage Hepatocellular Carcinoma: A Propensity Score Matching Study

AIMS: The purpose of the present study was to compare the efficacies of transarterial chemoembolization (TACE) combined with sorafenib versus TACE monotherapy for treating patients with advanced hepatocellular carcinoma (HCC). METHODS: We enrolled 321 patients and selected 280 with advanced HCC (Bar...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Hao, Duan, Zhenhua, Long, Xiaoran, Hertzanu, Yancu, Shi, Haibin, Liu, Sheng, Yang, Zhengqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4016022/
https://www.ncbi.nlm.nih.gov/pubmed/24817002
http://dx.doi.org/10.1371/journal.pone.0096620
_version_ 1782315449532284928
author Hu, Hao
Duan, Zhenhua
Long, Xiaoran
Hertzanu, Yancu
Shi, Haibin
Liu, Sheng
Yang, Zhengqiang
author_facet Hu, Hao
Duan, Zhenhua
Long, Xiaoran
Hertzanu, Yancu
Shi, Haibin
Liu, Sheng
Yang, Zhengqiang
author_sort Hu, Hao
collection PubMed
description AIMS: The purpose of the present study was to compare the efficacies of transarterial chemoembolization (TACE) combined with sorafenib versus TACE monotherapy for treating patients with advanced hepatocellular carcinoma (HCC). METHODS: We enrolled 321 patients and selected 280 with advanced HCC (Barcelona Clinic Liver Cancer stage C) who underwent TACE therapy between February 2009 and February 2013. TACE alone (monotherapy group) was administered to 198 patients (70.7%), and the remaining 82 (29.3%) underwent repeat combined TACE and sorafenib therapy (combined group). To minimize selection bias, these latter 82 patients were matched using propensity-score matching at a 1∶2 ratio with 164 patients who received TACE monotherapy. The primary endpoints were overall survival (OS) and related subgroup analysis. The secondary endpoints were time to progression (TTP) and treatment-related adverse events. RESULTS: Of the respective patients in the combined and monotherapy groups, 64.6% and 49.2% had vascular invasion, 87.8% and 91.1% had extrahepatic metastasis, and 54.3% and 47.1% had both. In the propensity-score–matched cohort, the OS survival of the combined group was significantly higher compared with the monotherapy group (7.0 months vs. 4.9 months, respectively, P = 0.003). The TTP was significantly longer in the combined group (2.6 months vs. 1.9 months, respectively, P = 0.001). Subgroup analysis showed that the outcomes of patients with advanced HCC without main portal vein invasion who were treated with combined therapy were significantly better compared with those who received monotherapy (P<0.05). Univariate and subsequent multivariate analyses revealed that the addition of sorafenib was an independent predictor of favorable OS and TTP (adjusted hazard ratios, 0.63 and 0.62, respectively; P<0.05 for both). CONCLUSION: Sorafenib plus TACE was more effective than TACE monotherapy for treating patients with advanced HCC without main portal vein invasion. Future trials with larger samples are required to validate these preliminary findings.
format Online
Article
Text
id pubmed-4016022
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-40160222014-05-14 Sorafenib Combined with Transarterial Chemoembolization versus Transarterial Chemoembolization Alone for Advanced-Stage Hepatocellular Carcinoma: A Propensity Score Matching Study Hu, Hao Duan, Zhenhua Long, Xiaoran Hertzanu, Yancu Shi, Haibin Liu, Sheng Yang, Zhengqiang PLoS One Research Article AIMS: The purpose of the present study was to compare the efficacies of transarterial chemoembolization (TACE) combined with sorafenib versus TACE monotherapy for treating patients with advanced hepatocellular carcinoma (HCC). METHODS: We enrolled 321 patients and selected 280 with advanced HCC (Barcelona Clinic Liver Cancer stage C) who underwent TACE therapy between February 2009 and February 2013. TACE alone (monotherapy group) was administered to 198 patients (70.7%), and the remaining 82 (29.3%) underwent repeat combined TACE and sorafenib therapy (combined group). To minimize selection bias, these latter 82 patients were matched using propensity-score matching at a 1∶2 ratio with 164 patients who received TACE monotherapy. The primary endpoints were overall survival (OS) and related subgroup analysis. The secondary endpoints were time to progression (TTP) and treatment-related adverse events. RESULTS: Of the respective patients in the combined and monotherapy groups, 64.6% and 49.2% had vascular invasion, 87.8% and 91.1% had extrahepatic metastasis, and 54.3% and 47.1% had both. In the propensity-score–matched cohort, the OS survival of the combined group was significantly higher compared with the monotherapy group (7.0 months vs. 4.9 months, respectively, P = 0.003). The TTP was significantly longer in the combined group (2.6 months vs. 1.9 months, respectively, P = 0.001). Subgroup analysis showed that the outcomes of patients with advanced HCC without main portal vein invasion who were treated with combined therapy were significantly better compared with those who received monotherapy (P<0.05). Univariate and subsequent multivariate analyses revealed that the addition of sorafenib was an independent predictor of favorable OS and TTP (adjusted hazard ratios, 0.63 and 0.62, respectively; P<0.05 for both). CONCLUSION: Sorafenib plus TACE was more effective than TACE monotherapy for treating patients with advanced HCC without main portal vein invasion. Future trials with larger samples are required to validate these preliminary findings. Public Library of Science 2014-05-09 /pmc/articles/PMC4016022/ /pubmed/24817002 http://dx.doi.org/10.1371/journal.pone.0096620 Text en © 2014 Hu et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Hu, Hao
Duan, Zhenhua
Long, Xiaoran
Hertzanu, Yancu
Shi, Haibin
Liu, Sheng
Yang, Zhengqiang
Sorafenib Combined with Transarterial Chemoembolization versus Transarterial Chemoembolization Alone for Advanced-Stage Hepatocellular Carcinoma: A Propensity Score Matching Study
title Sorafenib Combined with Transarterial Chemoembolization versus Transarterial Chemoembolization Alone for Advanced-Stage Hepatocellular Carcinoma: A Propensity Score Matching Study
title_full Sorafenib Combined with Transarterial Chemoembolization versus Transarterial Chemoembolization Alone for Advanced-Stage Hepatocellular Carcinoma: A Propensity Score Matching Study
title_fullStr Sorafenib Combined with Transarterial Chemoembolization versus Transarterial Chemoembolization Alone for Advanced-Stage Hepatocellular Carcinoma: A Propensity Score Matching Study
title_full_unstemmed Sorafenib Combined with Transarterial Chemoembolization versus Transarterial Chemoembolization Alone for Advanced-Stage Hepatocellular Carcinoma: A Propensity Score Matching Study
title_short Sorafenib Combined with Transarterial Chemoembolization versus Transarterial Chemoembolization Alone for Advanced-Stage Hepatocellular Carcinoma: A Propensity Score Matching Study
title_sort sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4016022/
https://www.ncbi.nlm.nih.gov/pubmed/24817002
http://dx.doi.org/10.1371/journal.pone.0096620
work_keys_str_mv AT huhao sorafenibcombinedwithtransarterialchemoembolizationversustransarterialchemoembolizationaloneforadvancedstagehepatocellularcarcinomaapropensityscorematchingstudy
AT duanzhenhua sorafenibcombinedwithtransarterialchemoembolizationversustransarterialchemoembolizationaloneforadvancedstagehepatocellularcarcinomaapropensityscorematchingstudy
AT longxiaoran sorafenibcombinedwithtransarterialchemoembolizationversustransarterialchemoembolizationaloneforadvancedstagehepatocellularcarcinomaapropensityscorematchingstudy
AT hertzanuyancu sorafenibcombinedwithtransarterialchemoembolizationversustransarterialchemoembolizationaloneforadvancedstagehepatocellularcarcinomaapropensityscorematchingstudy
AT shihaibin sorafenibcombinedwithtransarterialchemoembolizationversustransarterialchemoembolizationaloneforadvancedstagehepatocellularcarcinomaapropensityscorematchingstudy
AT liusheng sorafenibcombinedwithtransarterialchemoembolizationversustransarterialchemoembolizationaloneforadvancedstagehepatocellularcarcinomaapropensityscorematchingstudy
AT yangzhengqiang sorafenibcombinedwithtransarterialchemoembolizationversustransarterialchemoembolizationaloneforadvancedstagehepatocellularcarcinomaapropensityscorematchingstudy